What are the side effects of Pexidartinib?

In patients receiving pexidartinib for the treatment of tenosynovial giant cell tumor (TGCT), the most common (>20%) adverse reactions (including laboratory abnormalities) include increased lactate dehydrogenase (LDH), aspartate aminotransferase (AST) ), hair color changes, fatigue, increased alanine aminotransferase (ALT), neutropenia, increased cholesterol, increased serum alkaline phosphatase (ALP), lymphopenia, eye edema, decreased hemoglobin, rash, dysgeusia, and decreased phosphate. After it was put on the market, there was also an increase in blood creatine phosphokinase.

Serious adverse reactions, including abnormal liver function (3.3%) and hepatotoxicity (3.3%), were reported in 13% of patients treated with pexidartinib. 38% of patients who received pesidartinib experienced dose reduction or interruption. Common adverse reactions were increased ALT (13%), increased AST (13%), nausea (8%), increased ALP (7%), vomiting (4.9%), increased bilirubin (3.3%), dizziness (3.3%) and abdominal pain (3.3%). Thirteen percent of patients receiving pexidartinib permanently discontinued treatment due to adverse reactions, including ALT elevation (4.9%), AST elevation (4.9%), and hepatotoxicity (3.3%).

There are limited human data regarding pesidartinib overdose. In a 4-week toxicology study, the no-observed adverse effect levels (NOAELs) of pexidartinib were 10 mg/kg/day in rats and 6 mg/kg/day in dogs. Pesidartinib has been shown to cause hepatotoxicity, including mixed or cholestatic hepatotoxicity, in clinical trials, and embryono-fetal toxicity in animal studies.

Pesidartinib is not marketed in the country. There is less information on the price and other related information of pexidartinib after it is launched overseas. For more drug information and specific prices, please consult the medical consultant.